NCT05328024Recruiting
Identification of Predictive Factors for the Response to Anti-Programmed Cell Death Protein 1 (PD1) Immunotherapy in Head and Neck Squamous Cell Carcinoma
Source: ClinicalTrials.gov · Last updated 5 Jun 2026
Brief summary (registry, in English)
This project aims to organise the sampling of blood and tumor at key points of the standard of care of patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (HNSCC). This will allow to identify new potential predictive biomarkers of efficacy of immunotherapy and to investigate the evolution of the tumoral microenvironment after successive systemic treatments.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 60 (estimated)
- First submitted
- 7 Apr 2022
- Start date
- 25 Aug 2023
- Primary completion date
- 25 Aug 2029
- Lead sponsor
- Centre Paul Strauss
- Diseases
- Head and neck cancer
- NCT number
- NCT05328024
What you commit to
- Study type: Observational
- Planned participants: 60
- From 25 Aug 2023 to the primary completion date, 25 Aug 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with contraindication for anti-PD1 immunotherapy
Other illness
- Cancer of nasopharynx, sinus or nasal cavity
Other
- Head and neck squamous cell carcinoma accessible to a local treatment
- Other histology than epidermoid
Who the study is looking for
- Patients with recurrent squamous-cell carcinoma of the head and neck not amenable to local therapy and/or with metastatic disease
- Tumor directly accessible to clinical examination (tumor of oral cavity and of oropharynx) and/or cervical lymphadenopathy accessible to echography allowing to realise biopsy under local anesthesia
- Indication to treatment by anti-PD1 immunotherapy according to French competent authority recommendations
- Performance status 0, 1 or 2
- At least one measurable lesion on RECIST V1.1 criteria
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institut de Cancérologie Strasbourg Europe Coordinator of this site? Confirm its status | Strasbourg | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.